CureVac N.V. (CVAC)
Jan 6, 2026 - CVAC was delisted (reason: acquired by BNTX)
4.660
-0.010 (-0.21%)
Inactive · Last trade price
on Jan 5, 2026
CureVac Revenue
CureVac had revenue of 54.13M EUR in the quarter ending September 30, 2025, a decrease of -89.04%. This brings the company's revenue in the last twelve months to 70.74M, down -86.98% year-over-year. In the year 2024, CureVac had annual revenue of 535.18M with 895.54% growth.
Revenue (ttm)
70.74M EUR
Revenue Growth
-86.98%
P/S Ratio
9.02
Revenue / Employee
71,964 EUR
Employees
983
Market Cap
1.05B USD
Revenue Chart
* This company reports financials in EUR.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCVAC News
- 4 days ago - CureVac sues Moderna for patent infringement over COVID-19 vaccines - Reuters
- 5 months ago - BioNTech Achieves Minimum Condition in CureVac Exchange Offer - GlobeNewsWire
- 5 months ago - CureVac Announces Voting Results of Extraordinary General Meeting - Accesswire
- 5 months ago - CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2025 and Provides Business Updates - Accesswire
- 9 months ago - CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates - Accesswire
- 9 months ago - CureVac settles patent dispute litigation with Pfizer and BioNTech - Reuters
- 11 months ago - CureVac Announces Voting Results of General Meeting - Accesswire
- 11 months ago - Top Stock Movers Now: Oracle, Boeing, CureVac, and More - Investopedia